Velan Capital Investment Management LP Invests $817,000 in Avalo Therapeutics, Inc. (NASDAQ:AVTX)

Velan Capital Investment Management LP acquired a new stake in Avalo Therapeutics, Inc. (NASDAQ:AVTX) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 109,972 shares of the company’s stock, valued at approximately $817,000. Avalo Therapeutics accounts for about 0.7% of Velan Capital Investment Management LP’s holdings, making the stock its 18th biggest holding. Velan Capital Investment Management LP owned 1.06% of Avalo Therapeutics as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in AVTX. Tower Research Capital LLC TRC boosted its position in shares of Avalo Therapeutics by 998.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company’s stock valued at $31,000 after purchasing an additional 3,754 shares in the last quarter. Marshall Wace LLP acquired a new position in Avalo Therapeutics in the fourth quarter valued at approximately $114,000. Walleye Capital LLC bought a new position in shares of Avalo Therapeutics during the 4th quarter worth approximately $145,000. Northern Trust Corp acquired a new stake in shares of Avalo Therapeutics during the 4th quarter worth approximately $168,000. Finally, Bank of Montreal Can bought a new stake in shares of Avalo Therapeutics in the 4th quarter valued at $446,000. Institutional investors own 87.06% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on AVTX. Stifel Nicolaus began coverage on Avalo Therapeutics in a research note on Tuesday, March 25th. They set a “buy” rating and a $36.00 price target on the stock. HC Wainwright reissued a “neutral” rating on shares of Avalo Therapeutics in a research report on Thursday, March 20th. Jefferies Financial Group assumed coverage on Avalo Therapeutics in a research note on Tuesday, March 25th. They set a “buy” rating and a $23.00 price target for the company. Piper Sandler began coverage on Avalo Therapeutics in a research note on Friday, February 28th. They issued an “overweight” rating and a $48.00 price objective for the company. Finally, Wedbush reaffirmed an “outperform” rating and set a $18.00 target price on shares of Avalo Therapeutics in a research report on Thursday, March 20th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $33.00.

Avalo Therapeutics Stock Up 1.3%

Shares of AVTX opened at $3.91 on Monday. The stock has a 50 day moving average of $5.78 and a 200 day moving average of $7.76. Avalo Therapeutics, Inc. has a 12 month low of $3.39 and a 12 month high of $16.00.

Avalo Therapeutics (NASDAQ:AVTX) last announced its quarterly earnings data on Monday, May 12th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.18). Research analysts predict that Avalo Therapeutics, Inc. will post -19.07 earnings per share for the current year.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.